An observational study in Rectal Cancer, Rectal Adenocarcinoma and Rectal Adenoma, sponsored by Jagiellonian University. Not yet recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by Jagiellonian University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Rectal Neoplasms with a site in Poland — 4 open to participants now, 8 under way, 3 of them phase 3. Rectal Neoplasms · Poland.
Among the 31 studies in Rectal Neoplasms with a site in Poland, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 29th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →4 of the 31 studies in Rectal Neoplasms with a site in Poland are open now. Recruiting first, the newest first:
Medical University of Gdansk · Sites in Poland, France
Ages 18+
Merck Sharp & Dohme LLC · Sites in Poland, United States, Argentina and 26 more countries
Ages 18+
Maria Sklodowska-Curie National Research Institute of Oncology · Sites in Poland
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 11 · Phase 4 1
First in 1993; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 161 across 499 observational studies indexed under Rectal Neoplasms.
Median enrollment 260 across the 27 interventional studies, 300 across the 3 observational. Of the 15 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 31 have an industry lead sponsor. The 10 most frequent:
Jagiellonian University is the lead sponsor of 161 studies on the registry; 34 are open to participants now.
Jagiellonian University has 5 studies filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Rectal Neoplasms with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Rectal Neoplasms with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates how advanced endoscopic resection techniques affect treatment outcomes in adults with rectal cancer.
Rectal cancer has traditionally been treated with standard abdominal surgery. Newer endoscopic techniques allow removal of selected early tumors and may reduce treatment-related complications. However, their effectiveness and safety in tumors with deeper invasion are not yet fully established.
This multicenter retrospective observational study uses existing medical records from adults who underwent endoscopic or surgical resection of rectal tumors between 2015 and 2025. Researchers will analyze anonymized information on procedures performed and treatment outcomes to assess the safety and effectiveness of advanced endoscopic approaches.
The results of this study may help guide treatment selection and improve care for people with rectal cancer.
Patients with rectal neoplasms treated with advanced endoscopic resection in a tertiary center.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who underwent endoscopic submucosal dissection for rectal neoplasm
Procedure: Endoscopic submucosal dissection
Patients who underwent endoscopic intermuscular dissection for rectal neoplasm
Procedure: Endoscopic intramuscular dissection
Endoscopic submucosal dissection is an advanced endoscopic technique used to remove rectal tumors in one piece through the endoscope. A circumferential incision is then made in the mucosa, followed by careful dissection within the submucosal layer until the lesion is completely removed. This technique enables precise pathological assessment of tumor margins and depth of invasion and is typically used for lesions suspected to have superficial submucosal invasion without clear evidence of lymph node involvement. The procedure is performed using standard therapeutic endoscopic equipment and electrosurgical devices.
Endoscopic intermuscular dissection is an advanced endoscopic resection technique designed for rectal tumors with suspected deeper submucosal invasion. Following mucosal incision, the dissection is intentionally performed in the plane between the inner circular and outer longitudinal muscle layers of the rectal wall. This allows deeper en bloc tumor removal compared with conventional endoscopic submucosal dissection. The goal of this technique is to achieve complete resection while potentially avoiding radical surgery in selected patients. The procedure is performed endoscopically using specialized dissection knives and electrosurgical systems and requires advanced operator expertise.
Major intraprocedural bleeding rate
Bleeding occurring during the procedure that required advanced endoscopic hemostatic interventions beyond standard coagulation with the tip of the knife of coagulation forceps, resulted in hemodynamic instability, caused a significant prolongation of the procedure over 15 minutes (based on video), or led to procedure interruption or conversion
Time frame: During the procedure
Intraprocedural perforation rate
Full-thickness defect of the gastrointestinal wall identified during the procedure, evidenced by direct visualization of extraluminal structures (mesorectum or peritoneal cavity), or confirmed by the presence of free air on imaging performed immediately after the procedure.
Time frame: During the procedure
Delayed bleeding rate
Symptomatic bleeding including hematemesis, melena, or a hemoglobin decrease of more than 2 g/dL.
Time frame: Within 28 days after the procedure
Delayed perforation rate
Clinical signs of peritonitis accompanied by radiological evidence of free intraperitoneal air.
Time frame: Within 14 days after the procedure
Post-coagulation syndrome rate
The occurrence of localized abdominal pain or peritoneal irritation signs after EID, accompanied by inflammatory response (elevated white blood cell count or C-reactive protein), in the absence of radiological or endoscopic evidence of perforation.
Time frame: Within 28 days following the procedure
The need for emergency interventions
Any unplanned therapeutic intervention related to the index procedure during hospitalization or follow-up, including repeat endoscopy, endoscopic or radiological intervention, blood transfusion, or surgical treatment. Planned surveillance procedures were not considered additional interventions.
Time frame: Within 30 days after the procedure
Procedure-related mortality rate
Number of deaths occurring within 30 days of the index procedure that was directly attributable to the procedure or to procedure-related complications. Deaths unrelated to the procedure were reported but not considered procedure-related mortality.
Time frame: Within 30 days after the procedure
En bloc resection rate
The rate of lesions removed in a single specimen, enabling accurate macroscopic and histological assessment as reported by an endoscopist in a procedure protocol.
Time frame: Intraprocedural
Complete resection rate
The rate of lesions resected completely according to the pathological examination of the resected specimen.
Time frame: Within 30 days after the procedure
Procedure time
Procedure time was evaluated on the procedure video and defined as the interval from the insertion of the scope to its final withdrawal measured in minutes; anesthesia-related time was not included.
Time frame: Intraprocedural
Length of hospital stay
The number of days from the day of the procedure (day 0) to the day of hospital discharge.
Time frame: Within 30 days after the procedure
The need for additional treatment
The number of patients who required completion surgery or adjuvant (chemo)radiotherapy.
Time frame: Within 12 months after the procedure
Plan to share: No — Permission for data sharing was not included in the bioethics committee approval.
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Apr 2026, 1 month later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.